Genetic characteristics at progression of disease
| . | Value (n = 75) . |
|---|---|
| No. of cytogenetic abnormalities | |
| Median (range) | 5 (0 to ≥20) |
| No. (%) | |
| 0 | 3 (4) |
| 1-2 | 15 (20) |
| 3-4 | 12 (16) |
| 5-9 | 27 (36) |
| 10-14 | 6 (8) |
| ≥15 | 12 (16) |
| Change in number of cytogenetic abnormalities from ibrutinib start to progression | |
| Median (range) | 1 (–8 to 13) |
| No. (%) | |
| No change or decrease in abnormalities | 33 (44) |
| Increase in abnormalities | 42 (56) |
| Karyotype evolution | 60 (80) |
| . | Value (n = 75) . |
|---|---|
| No. of cytogenetic abnormalities | |
| Median (range) | 5 (0 to ≥20) |
| No. (%) | |
| 0 | 3 (4) |
| 1-2 | 15 (20) |
| 3-4 | 12 (16) |
| 5-9 | 27 (36) |
| 10-14 | 6 (8) |
| ≥15 | 12 (16) |
| Change in number of cytogenetic abnormalities from ibrutinib start to progression | |
| Median (range) | 1 (–8 to 13) |
| No. (%) | |
| No change or decrease in abnormalities | 33 (44) |
| Increase in abnormalities | 42 (56) |
| Karyotype evolution | 60 (80) |